174 related articles for article (PubMed ID: 11024351)
1. Candidate multi-epitope vaccines in aluminium adjuvant induce high levels of antibodies with predefined multi-epitope specificity against HIV-1.
Ding J; Lu Y; Chen Y
FEMS Immunol Med Microbiol; 2000 Oct; 29(2):123-7. PubMed ID: 11024351
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
[TBL] [Abstract][Full Text] [Related]
3. HIV epitope-peptides in aluminum adjuvant induced high levels of epitope-specific antibodies.
Tian H; Xiao Y; Zhu M; Chen YH
Int Immunopharmacol; 2001 Apr; 1(4):763-8. PubMed ID: 11357888
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and specificity of the candidate multi-epitope-vaccines against HIV-1.
Lu Y; Ding J; Chen YH
Immunopharmacol Immunotoxicol; 2001 Nov; 23(4):487-94. PubMed ID: 11792008
[TBL] [Abstract][Full Text] [Related]
5. Multiepitope vaccines intensively increased levels of antibodies recognizing three neutralizing epitopes on human immunodeficiency virus-1 envelope protein.
Lu Y; Xiao Y; Ding J; Dierich MP; Chen YH
Scand J Immunol; 2000 May; 51(5):497-501. PubMed ID: 10792842
[TBL] [Abstract][Full Text] [Related]
6. Antigenicity and predefined specificities of the multi-epitope vaccine in candidate consisting of neutralizing epitope and mutated epitopes suggested a new way against HIV-1 mutation.
Tian H; Xiao Y; Qin L; Chen YH
Immunobiology; 2001 Dec; 204(4):434-41. PubMed ID: 11776398
[TBL] [Abstract][Full Text] [Related]
7. Induction of high levels of epitope-specific antibodies by epitope/peptide candidate vaccines against human immunodeficiency virus type-1 (HIV-1).
Yu T; Bai Y; Dierich MP; Chen YH
Microbiol Immunol; 2000; 44(2):105-10. PubMed ID: 10803497
[TBL] [Abstract][Full Text] [Related]
8. Epitope-vaccines: a new strategy to induce high levels of neutralizing antibodies against HIV-1.
Xiao Y; Liao M; Lu Y; Dierich MP; Chen YH
Immunobiology; 2000 Jan; 201(3-4):323-31. PubMed ID: 10776789
[TBL] [Abstract][Full Text] [Related]
9. Induction of high levels of antibodies recognizing the neutralizing epitope ELDKWA and the D- or K-position-mutated epitopes by candidate epitope vaccines against HIV-1.
Xiao Y; Dong X; Chen Y
Int Arch Allergy Immunol; 2000 Aug; 122(4):287-92. PubMed ID: 10971120
[TBL] [Abstract][Full Text] [Related]
10. Recombinant multi-epitope vaccine induce predefined epitope-specific antibodies against HIV-1.
Li H; Liu ZQ; Ding J; Chen YH
Immunol Lett; 2002 Nov; 84(2):153-7. PubMed ID: 12270553
[TBL] [Abstract][Full Text] [Related]
11. A predefined epitope-specific monoclonal antibody recognizes ELDEWA-epitope just presenting on gp41 of HIV-1 O clade.
Huang J; Dong X; Liu Z; Qin L; Chen YH
Immunol Lett; 2002 Dec; 84(3):205-9. PubMed ID: 12413738
[TBL] [Abstract][Full Text] [Related]
12. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
Dong XN; Xiao Y; Chen YH
Immunol Lett; 2001 Jan; 75(2):149-52. PubMed ID: 11137140
[TBL] [Abstract][Full Text] [Related]
13. The recombinant immunogen with high-density epitopes of ELDKWA and ELDEWA induced antibodies recognizing both epitopes on HIV-1 gp41.
Wang Z; Liu Z; Cheng X; Chen YH
Microbiol Immunol; 2005; 49(8):703-9. PubMed ID: 16113499
[TBL] [Abstract][Full Text] [Related]
14. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody.
Xiao Y; Zhao Y; Lu Y; Chen YH
Immunol Invest; 2000 Feb; 29(1):41-50. PubMed ID: 10709845
[TBL] [Abstract][Full Text] [Related]
15. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine.
Xiao Y; Dong XN; Chen YH
Hybridoma; 2000 Aug; 19(4):347-50. PubMed ID: 11001409
[TBL] [Abstract][Full Text] [Related]
16. Induction of high level of specific antibody response to the neutralizing epitope ELDKWA on HIV-1 gp41 by peptide-vaccine.
Liao M; Lu Y; Xiao Y; Dierich MP; Chen Y
Peptides; 2000 Apr; 21(4):463-8. PubMed ID: 10822100
[TBL] [Abstract][Full Text] [Related]
17. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
18. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
Zhang G; Chen YH
Immunobiology; 2003; 207(4):259-64. PubMed ID: 12952348
[TBL] [Abstract][Full Text] [Related]
19. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
20. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120.
Karle S; Nishiyama Y; Taguchi H; Zhou YX; Luo J; Planque S; Hanson C; Paul S
Vaccine; 2003 Mar; 21(11-12):1213-8. PubMed ID: 12559800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
